Aashish Kumar, Deepak Rajani, Satesh Kumar – 27 April 2022
Rujittika Mungmunpuntipantip, Viroj Wiwanitkit – 27 April 2022
Nupur Sharma, Manisha Yadav, Gaurav Tripathi, Babu Mathew, Vasundhra Bindal, Sanyam Falari, Viniyendra Pamecha, Jaswinder Singh Maras – 27 April 2022
Pimsiri Sripongpun, W. Ray Kim, Ajitha Mannalithara, Vivek Charu, Anna Vidovszky, Steven Asch, Manisha Desai, Sun H. Kim, Allison J. Kwong – 27 April 2022
Shi‐Tao Jiang, Lei Zhang, Yi‐Yao Xu, Xin Lu – 27 April 2022
Rohini Sharma, Anjana Pillai, Thomas Urban Marron, Petros Fessas, Anwaar Saeed, Tomi Jun, Sirish Dharmapuri, David Szafron, Abdul Rafeh Naqash, Anuhya Gampa, Yinghong Wang, Uqba Khan, Mahvish Muzaffar, Chieh‐Ju Lee, Pei‐Chang Lee, Anushi Bulumulle, Sonal Paul, Dominic Bettinger, Hannah Hildebrand, Mohammed Yehia, Tiziana Pressiani, Ahmed Kaseb, Yi‐Hsiang Huang, Celina Ang, Masatoshi Kudo, Naoshi Nishida, Nicola Personeni, Lorenza Rimassa, David James Pinato – 27 April 2022 – The availability of immune checkpoint inhibitors (ICIs) for the management of advanced hepatocellular cancer (HC
Yoshihiro Kamada, Takashi Nakahara, Kensuke Munekage, Hideki Fujii, Yoshiyuki Sawai, Yoshinori Doi, Masafumi Ono, Hideyuki Hyogo, Yoshio Sumida, Koichi Morishita, Tatsuya Asuka, Tsunenori Ouchida, Yasuharu Imai, Eiji Miyoshi, Japan Study Group of NAFLD – 26 April 2022 – We previously demonstrated that Mac‐2 binding protein (M2BP) is a useful biomarker for nonalcoholic fatty liver disease (NAFLD), particularly NAFLD fibrosis prediction. In the present study, we investigated the prognostic value of M2BP in patients with NAFLD.
AASLD develops evidence-based practice guidelines and practice guidances which are updated regularly by a multi-disciplinary panel of experts, including hepatologists, and include recommendations of preferred approaches to the diagnostic, therapeutic, and preventive aspects of care.
Manhal Izzy, Hilary M. DuBrock – 25 April 2022
Manhal Izzy, Hilary M. DuBrock – 25 April 2022